An anonymous EU official said the bloc will pay less than $19.50 per dose for 200 million doses of the vaccine, with the option to buy another 100 million, according to Al Jazeera.
The U.S. inked a deal with Pfizer July 22, in which HHS and the defense department agreed to pay $19.50 for 100 million doses of the vaccine. The U.S. has the option to buy 500 million more doses, but terms will be negotiated separately and the price for those additional doses is uncertain.
The anonymous source said the reason the EU is initially paying less than the U.S. could be that it gave financial support to the vaccine’s development, which Pfizer is conducting with German drugmaker BioNTech, according to Al Jazeera.
More articles on pharmacy:
18 generic drugmakers unite to speed access to COVID-19 treatments
Cardinal Health, CDC partner to give pharmacies COVID-19 vaccine access
Pfizer CEO sold $5.6M in stock after positive COVID-19 vaccine announcement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
